Vicapsys Life Sciences Provides Shareholder Update on VICAPSYN(TM) Program Advancing Toward Phase 1 Human Clinical Trial, Vertically Integrated With the Company’s Indian Health Service Strategy
VICAPSYN™, the Company's immune-isolation technology for islet cell transplantation in type 1 diabetes, remains an active asset of Vicapsys and...